ARTICLE | Clinical News
Influenza vaccine: Phase III data
September 8, 2008 7:00 AM UTC
Data from 1,341 evaluable healthy volunteers in a double-blind, placebo-controlled, U.S. Phase III trial, showed that Afluria met the primary endpoint of producing 40% seroconversion and 70% seroprote...